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Abstract
Financial crisis has forced health systems to seek alternatives to hospitalization-based healthcare. Quick diagnosis units (QDUs) are
cost-effective compared to hospitalization, but the determinants of QDU costs have not been studied.
We aimed at assessing the predictors of costs of a district hospital QDU (Hospital Plató, Barcelona) between 2009 and 2016.
This study was a retrospective longitudinal single center study of 404 consecutive outpatients referred to the QDU of Hospital
Plató. The referral reason was dichotomized into suggestive of malignancy vs other. The final diagnosis was dichotomized into
organic vs nonorganic andmalignancy vs nonmalignancy. All individual resource costs were obtained from the finance department to
conduct a micro-costing analysis of the study period.
Mean age was 62±20 years (women=56%), andmedian time-to-diagnosis, 12 days. Total and partial costs were greater in cases
with final diagnosis of organic vs nonorganic disorder, as it was in those with symptoms suggestive or a final diagnosis of cancer vs
noncancer. Of all subcosts, imaging showed the stronger correlation with total cost. Time-to-diagnosis and imaging costs were
significant predictors of total cost above the median in binary logistic regression, with imaging costs also being a significant predictor
in multiple linear regression (with total cost as quantitative outcome).
Predictors of QDU costs are partly nonmodifiable (i.e., cancer suspicion, actually one of the goals of QDUs). Yet, improved primary-
care-to-hospital referral circuits reducing time to diagnosis as well as optimized imaging protocols might further increase the QDU
cost-effectiveness process. Prospective studies (ideally with direct comparison to conventional hospitalization costs) are needed to
explore this possibility.
Abbreviations: CI = confidence interval, Q1–Q3 = inter-quartile range, QDU = quick diagnosis unit.
Keywords: direct costs, indirect costs, micro-costing, public health system, quick diagnosis units
1. Introduction
Lessons learned from the last economic crisis allowed to better
understand that to maximize outcomes that matter to patients,
the affordability and sustainability of public health systems could
only be achieved by undertaking deep reforms. In some European
countries, such reforms included not funding tests and treatments
lacking evidence of its value (as in the case of the National
Institute of Clinical Excellence guides[1] in the United Kingdom).
In Spain, the economic crisis did not result in structural changes in
the health system, because these changes would probably take too
long in the setting of short political terms. Accordingly, almost all
policies have been contingence actions to reduce costs.[2,3] While
some of these actions proved successful, like the use of generic
drug policy, which led to lowering of drug prices, or exclusion
from public funding of drugs lacking enough evidence of benefit,
other policies had negative results.[4,5] This is the case of
copayment without exclusion of frail population, reduction of
salaries of health workers, or higher taxes to health products.
These negative effects have rebounded on healthcare quality and
its indicators such as waiting lists or times between diagnosis and
treatment. Other factors with a negative impact on the
sustainability of the health system include structural debts, an
increasing incidence of chronic conditions, the aging of the
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population, expensive ancillary tests (and their use without
standardized proceedings), and excessive medicalization.
An important avenue to facilitate the sustainability of public
health systems has been the implementation of alternatives to
hospitalization-based medicine.[6] Well-established examples
include alternatives to hospitalization for treatment and
follow-up such as ambulatory surgery, hospital at-home, day-
care hospitals and telemedicine, or, for diagnosis, most notably
quick diagnosis units (QDUs).
In terms of QDU, the first reported experience took place in the
United Kingdom, at the Queen Elizabeth Hospital, in Birming-
ham, where an outward approach for cancer diagnoses was
proposed, based on specialty doctors visit according to main
symptoms. In Catalonia, the QDU started on 1996, when the
results of the UKQDUwere published.[7] It is known that around
15% to 20% of Spanish Internal Medicine admissions are for
diagnostic purposes.[8,9] Thus such admissions could be
potentially avoided or diminished. Internal medicine specialists
lead Catalan QDUs, which gives a wide approach to the patients
who usually have nonspecific symptoms (as usually happens at
time of cancer presentation).
Over the last 15 years several QDUs have been set up in
Catalonia as a mean of reaching diagnoses rapidly and
without the problems and costs related to hospitalization[10].
There are QDUs in almost all types of hospitals, from university
(like Hospital Clínic de Barcelona)[11] to small district ones (like
Hospital Plató)[12]. Despite the spread of these QDUs, the
available evidence on their activity and the predictors of their
time-to-diagnosis and cost outcomes is scanty, particularly in the
case of nonuniversity, nontertiary centers. The QDU of Hospital
Plató was created in 2009 and is integrated in the Internal
Medicine Department of this hospital and the Hospital Clínic is
its reference center. We recently published a descriptive study of
the activity of a district hospital QDU (Hospital Plató) over a 6-
year time (2009–2016), comparing it to a reference university
hospital QDU (Hospital Clínic de Barcelona’s QDU). The main
finding was that despite clear-cut differences between these
hospitals, both had a similar effectiveness. However, in that
study, we did not tackle time to diagnosis, costs, and their
predictors.
Themain objective of the present studywas to describe the time
to diagnosis and the costs of the QDU of a district hospital
(Hospital Plató) with focus on the general costs of the QDU
patients visited in this unit during a 7-year study period. We also
aimed at assessing the potential predictors of longer time-to-
diagnosis and greater costs. We hypothesized that while organic
conditions in general and cancer in particular are more costly
than nonorganic and noncancer cases, respectively, the latter
increase time-to-diagnosis and result in avoidable costs. We also
hypothesized that part of the diagnostic tests drives the increase in
cost per case, offering an avenue for protocolling their use and
potentially allowing for further reduction in time-to-diagnosis
and cost-reduction.
2. Materials and methods
2.1. Setting
This study was conducted in the QDU of an urban district
hospital (Hospital Plató) in Barcelona, Catalonia, Spain. This
center has 160 beds for acute patients and is the healthcare
provider for a population of 140,000 inhabitants. The unit
evaluates patients with suspected severe conditions whose
physical performance allows them to travel from home to
hospital and back for visits and examinations. Similar to
inpatients, diagnostic tests are preferentially arranged.
2.2. Study design and population
This is a retrospective longitudinal study of 404 consecutive
patients aged ≥18 years who were referred to QDU between
November 2009 and December 2016.
The study was approved by the research ethics committee of
the network of hospitals to which Hospital Plató belongs (CEIC-
Unió Catalana d’Hospitals). The need for informed consent was
waived for QDU patients due to the retrospective design.
2.3. Database
Data from all the patients evaluated were recorded onto case
report forms and codified in a database. The variables recorded
were the same as reported elsewhere.[12] The information on the
number and dates of the appointments at the QDU and the
diagnostic tests as well as the reason for referral and the final
diagnosis were obtained from the hospital electronic clinical
records. The referral reason was dichotomized into clinical or
paraclinical features suggestive of malignancy vs other referral
reasons (see supplementary material, http://links.lww.com/MD/
E593) for statistical analyses purposes. Likewise, the final
diagnosis was dichotomized into organic vs nonorganic (organic
pathology defined as when symptoms and signs have a biologic
explanation and it is found during the diagnostic process) and as
malignancy vs nonmalignancy. Additionally, the micro-costing
study was carried out retrospectively to know the cost of each
patient evaluated at the QDU, considering all the diagnostic tests
performed and its costs to the hospital according to the finance
department of the hospital. The costs of all the resources
identified were also obtained from the finance department. Staff
time dedicated toQDUwas obtained according to the cumulative
time dedicated to this unit, multiplied by the average hourly wage
of the staff category. The same was done with other involved
health professionals times. The costs of small and big
consumables were included when indicated. The costs of
diagnostic procedures such as laboratory tests, radiology
explorations, or endoscopies were directly calculated using the
unit cost of the test to the hospital. Accordingly, the variables of
cost per each procedure, as well as the indirect costs and finally
the total cost per each case were introduced in the database. The
latter (the total cost per case) was the main outcome variable of
the study and as such for statistical analyses purposes it was
treated both as a quantitative variable and dichotomized
according to the median of the study cohort.
2.4. Statistical analysis
Descriptive statistics of qualitative variables are expressed as
absolute and relative frequencies, and those of quantitative
variables are presented as mean values with standard deviations
and median values with inter-quartiles (Q1Q3). Qualitative
variables were compared by means of Chi-squared or Fisher
exact test. All quantitative variables were compared by means of
Mann–Whitney U test due to skewed distribution of these
variables. Linear correlations were checked for with Spearman
test. To identify predictors of the total cost, we carried out
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multiple linear regression analyses (with total cost as quantitative
dependent variable) and binary logistic regression analyses (with
total cost dichotomized as detailed above as binary dependent
variable). In these multiple linear and binary logistic regression
models, several clinical and partial cost variables were introduced
as potential predictors. These were selected after the a priori
hypotheses and also due to significant unadjusted bivariate linear
correlation with the outcome variable. The multiple linear
regression analysis results are presented as the beta and B
coefficients (the latter with their 95% confidence intervals [CIs])
and the binary logistic regression models are expressed with their
respective odds ratios and 95% CIs. The threshold for
significance was set at P< .05 (all tests 2-tailed). All analyses
were performed with SPSS version 23 (IBM, New York City,
NY).
3. Results
3.1. Descriptive analysis of the entire cohort
Two hundred twenty-seven of the subjects were women (56%).
Mean age was 62 ± 20 years and the median time-to-diagnosis
Table 1
Descriptive statistics of the entire QDU cohort from Hospital Plató.
Entire cohort (n=406) Man Women P value
Sex (women) 227 (56%) 179 227 NA
Age, yrs 62±20 62.48 ± 19.88 61.33 ± 19.65 .46
65 (46–78) 66.00 (50.0–79.0) 64 (45–78)
Time-to-diagnosis, d 23 ± 34 26.82 ± 39.72 20.52 ± 29.41 .34
12 (1–28) 14 (0.0–32.75) 10 (2–28)
Referral reason (cancer suggestive features) 106 (26%) 55 (31%) 51 (22%) .07
Final diagnosis (organic cause) 319 (79%) 140 (78%) 179 (79%) .69
Final diagnosis (cancer) 58 (14%) 27 (15%) 31 (14%) .78
Physician costs 38.20 ± 13.50 38.47 ± 13.65 37.98 ± 13.40 .71
36.37 (24.25–48.50) 36.37 (24.25–48.50) 36.37 (24.25–48.50)
Laboratory costs 108.09 ± 93.57 111.83 ± 102.91 105.14 ± 85.60 .48
146.92 (0.00–146.92) 146.92 (0.00–146.92) 146.92 (0.00–146.92)
Imaging costs 129.45 ± 284.19 139.48 ± 340.08 121.54 ± 231.29 .75
16.68 (0.00–160.26) 19.10 (0.00–195.66) 16.68 (0.00–144.91)
Cytology/biopsy costs 15.01 ± 60.85 17.89 ± 66.27 12.74 ± 56.26 .40
0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00)
Pathology costs 1.95 ± 4.37 2.01 ± 4.46 1.90 ± 4.31 .90
0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00)
Other medical consultation costs 6.51 ± 10.89 6.64 ± 10.84 6.41 ± 10.96 .77
0.00 (0.00–24.25) 0.00 (0.00–24.25) 0.00 (0.00–24.25)
Endoscopy costs 21.75 ± 60.23 19.02 ± 57.09 23.91 ± 62.65 .43
0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00)
Surgeon consultation costs 2.87 ± 7.84 3.12 ± 8.14 2.67 ± 7.61 .57
0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00)
Anesthetist consultation costs 4.75 ± 11.90 4.24 ± 11.35 5.16 ± 12.33 .44
0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00)
Operation room costs 4.29 ± 50.08 1.81 ± 24.24 6.25 ± 63.43 .44
0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00)
Admissions costs 40.12 ± 390.65 47.73 ± 485.39 34.11 ± 310.32 .77
0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00)
Costs of referral to tertiary hospital 4.91 ± 35.40 6.60 ± 43.44 3.58 ± 27.50 .31
0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00)
Structural costs 5.08 ± 2.64 5.14 ± 2.66 5.03 ± 2.62 .63
4.73 (2.37–7.10) 4.73 (2.37–7.10) 4.73 (2.37–7.10)
Indirect costs type 1 2.05 ± 1.22 2.06 ± 1.17 2.04 ± 1.26 .64
1.71 (1.14–2.57) 1.71 (0.86–2.57) 1.71 (1.24–2.57)
Indirect costs type 2 0.44 ± 0.32 0.44 ± 0.30 0.44 ± 0.34 .70
0.33 (0.28–0.49) 0.33 (0.16–0.49) 0.33 (0.33–0.49)
Indirect costs type 3 2.66 ± 1.46 2.68 ± 1.43 2.64 ± 1.48 .60
2.35 (1.36–3.52) 2.35 (1.17–3.52) 2.35 (1.42–3.52)
Indirect costs type 4 7.24 ± 3.68 7.33 ± 3.79 7.17 ± 3.59 .70
6.94 (3.47–9.20) 6.94 (3.47–10.00) 6.94 (3.47–9.20)
Indirect costs type 5 0.99 ± 0.51 0.10 ± 0.52 0.98 ± 0.51 .58
0.91 (0.47–1.37) 0.91 (0.46–1.37) 0.91 (0.47–1.37)
Total cost, € 394,21 ± 582.64 417.45 ± 671.17 375.86 ± 502.77 .92
259.97 (141.13–451.25) 237.55 (149.25–461.24) 263.53 (136.98–441.24)
Data expressed as n (%) or mean ± standard deviation and median (interquartile range).
Indirect cost type 1 = activity-related outpatient unitary drug cost, indirect cost type 2 = remainder drug cost split across healthcare episodes, indirect cost type 3 = activity-adjusted unitary outpatients’ material
cost, indirect cost type 4 = activity-adjusted unitary material cost of other units supporting the quick diagnosis unit (QDU) activity, indirect cost type 5 = remainder material costs split across healthcare episodes,
NA=not applicable.
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was 12 days. Around one quarter of the cases were referred due to
cancer suggestive features andmost of the patients received a final
diagnosis of an organic disorder, but of those, <20% were
cancer. The median total cost was 259.97€ (for the partial costs,
see Table 1).When comparing all the study variables according to
sex, there were no statistically significant differences (Table 2).
3.2. Comparison of demographic, clinical, and costs data
according to referral reason and final diagnosis
3.2.1. Referral due to cancer vs noncancer suggestive
features. These 2 subgroups did not statistically differ in either
sex, age, time to diagnose, or the proportion of organic final
diagnosis. Nevertheless, the proportion of cases with a final
diagnosis of cancer was 5 times greater in patients referred for
cancer-suggestive feature. In terms of costs, both the total cost
and several partial costs (imaging, cytology, pathology, surgical,
structural and indirect costs) were significantly greater in cases
referred due to cancer suggestive features (Table 2).
3.2.2. Organic vs nonorganic final diagnosis. As in the
previous case, there were no differences in basic demographic
and clinical data. The proportion of cancer cases was significantly
greater in the former group than in the latter. In patients with a
Table 2
Comparative statistics between cases referred due to cancer suggestive features vs other symptoms.
Cancer suggestive features (n=106) Other symptoms (n=300) P value
Sex (women) 51 (48%) 176 (59%) .07
Age, yrs 62.24 ± 19.71 61.7 ± 19.78 .79
69 (46–77.5) 65 (46–78)
Time-to-diagnosis, d 19.53 ± 26.12 24.63 ± 36.87 .97
12 (5.00–25.75) 12 (0–30)
Final diagnosis (organic cause) 86 (81%) 233 (78%) .46
Final diagnosis (cancer) 37 (35%) 21 (7%) <.000001
∗
Physician costs 41.06 ± 13.75 37.18 ± 13.28 .004
∗
36.37 (36.37–48.50) 36.37 (24.25–45.47)
Laboratory costs 115.07 ± 115.42 105.61 ± 84.60 .30
146.92 (0.00–146.92) 146.92 (0.00–146.92)
Imaging costs 264.35 ± 441.82 81.79 ± 179.20 <.000001
∗
137.78 (0.00–301.81) 0.00 (0.00–109.13)
Cytology/biopsy costs 43.00 ± 96.76 5.12 ± 36.77 <.000001
∗
0.00 (0.00–39.75) 0.00 (0.00–0.00)
Pathology costs 4.03 ± 5.79 1.21 ± 3.47 <.000001
∗
0.00 (0.00–7.83) 0.00 (0.00–0.00)
Other medical consultation costs 8.01 ± 11.94 5.98 ± 10.47 .13
0.00 (0.00–24.25) 0.00 (0.00–0.00)
Endoscopy costs 25.05 ± 64.58 20.59 ± 58.70 .52
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Surgeon consultation costs 5.26 ± 10.04 2.02 ± 6.71 <.000001
∗
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Anesthetist consultation costs 6.50 ± 13.55 4.14 ± 11.22 .08
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Operation room costs 6.23 ± 45.14 3.61 ± 51.77 .27
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Admissions costs 22.67 ± 208.83 46.28 ± 444.58 .69
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Costs of referral to tertiary hospital 2.35 ± 24.18 5.81 ± 38.59 .24
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Structural costs 5.62 ± 2.70 4.89 ± 2.59 .02
∗
4.73 (4.73–7–10) 4.73 (2.37–6.51)
Indirect costs type 1 2.27 ± 1.23 1.97 ± 1.21 .007
∗
1.71 (1.71–2.57) 1.71 (0.86–2.55)
Indirect costs type 2 0.49 ± 0.32 0.42 ± 0.32 .01
∗
0.33 (0.33–0.65) 0.33 (0.16–0.49)
Indirect costs type 3 2.95 ± 1.47 2.56 ± 1.44 .005
∗
2.35 (2.35–3.52) 2.35 (1.17–3.44)
Indirect costs type 4 8.04 ± 3.77 6.96 ± 3.60 .003
∗
6.94 (6.13–10.40) 6.94 (3.47–8.64)
Indirect costs type 5 1.09 ± 0.52 0.95 ± 0.50 .008
∗
0.91 (0.91–1.37) 0.91 (0.46–1.26)
Total cost, € 564.06 ± 595.02 334.20 ± 567.13 <.000001
∗
430.75 (200.26–769.33) 220.87 (118.04–389.36)
Data expressed as n (%) or mean ± standard deviation and median (interquartile range).
Indirect cost type 1 = activity-related outpatient unitary drug cost, indirect cost type 2 = remainder drug cost split across healthcare episodes, indirect cost type 3 = activity-adjusted unitary outpatients’ material
cost, indirect cost type 4 = activity-adjusted unitary material cost of other units supporting the quick diagnosis unit activity, indirect cost type 5 = remainder material costs split across healthcare episodes.
∗
Statistically significant differences.
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final diagnosis of an organic disorder, the total and partial
(cytology, pathology, medical consultations, endoscopy, and
surgical and anaesthetist costs) costs were significantly greater
than in patients with a nonorganic disorder diagnosis (Table 3).
3.2.3. Cancer vs noncancer final diagnosis. In this set of
comparisons, cases with a final cancer diagnosis were signifi-
cantly older and had a greater proportion of referrals due to
cancer suggestive features. Cancer cases exhibited significantly
greater total costs, mainly due to significantly greater partial costs
in the following areas: physician costs, imaging, cytology,
pathology, other medical consultations, surgeon and anaesthetist
consultations, operation room, admissions and indirect costs
(Table 4).
3.3. Comparison of demographic, clinical, and partial
costs data according to time-to-diagnosis and total cost
3.3.1. Time-to-diagnosis greater vs smaller than the cohort
median. These 2 groups did not differ in any of the demographic
or clinical variables. The group with a prolonged diagnostic time
had significantly greater costs, both total and the following
partial costs: physician and laboratory costs, imaging, pathology,
Table 3
Comparative statistics between final organic vs nonorganic diagnosis.
Organic final diagnose (n=319) Nonorganic final diagnose (n=72) P value
Sex (women) 179 (56%) 38 (53%) .69
Age, yrs 62.26 ± 19.44 59.57 ± 21.41 .38
65 (48–78) 62.5 (43–79)
Time-to-diagnosis, d 23.29 ± 35.26 22.65 ± 29.76 .91
12 (1.75–28.25) 13 (0.50–27.75)
Referral reason (cancer suggestive features) 86 (27%) 16 (22%) .46
Final diagnosis (cancer) 58 (18%) 0 (0%) .000004
∗
Physician costs 38.27± 13.15 36.21 ± 10.86 .33
36.37 (24.25–48.50) 36.37 (24.25–36.37)
Laboratory costs 110.16 ± 97.31 97.39 ± 75.16 .73
146.92 (0.00–146.92) 146.92 (0.00–146.92)
Imaging costs 138.55 ± 306.34 64.37 ± 93.28 .10
16.68 (0.00–179.84) 0.00 (0.00–109.13)
Cytology/biopsy costs 19.02 ± 68.11 0.00 ± 0.00 .002
∗
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Pathology costs 2.35 ± 4.71 0.22 ± 1.30 <.000001
∗
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Other medical consultation costs 7.60 ± 11.43 2.02 ± 6.75 <.000001
∗
0.00 (0.00–24.25) 0.00 (0.00–0.00)
Endoscopy costs 24.72 ± 63.63 7.66 ± 37.01 .030
∗
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Surgeon consultation costs 3.42 ± 8.45 0.34 ± 2.86 .003
∗
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Anesthetist consultation costs 3.40 ± 12.55 1.44 ± 6.94 .010
∗
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Operation room costs 5.47 ± 56.47 0.00 ± 0.00 .34
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Admissions costs 51.06 ± 447.01 0.00 ± 0.00 .24
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Costs of referral to tertiary hospital 6.25 ± 39.85 0.00 ± 0.00 .13
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Structural costs 5.09 ± 2.57 4.70 ± 2.12 .23
4.73 (2.37–7.10) 4.73 (2.37–4.73)
Indirect costs type 1 2.08 ± 1.21 1.76 /- 0.83 .13
1.71 (1.24–2.57) 1.71 (0.86–1.71)
Indirect costs type 2 0.45 ± 0.32 0.35 ± 1.19 .03
∗
0.33 (0.33–0.49) 0.33 (0.16–0.33)
Indirect costs type 3 2.68 ± 1.44 2.37 ± 1.08 .08
2.35 (1.42–3.52) 2.35 (1.17–2.35)
Indirect costs type 4 7.24 ± 3.56 6.82 ± 3.08 .86
6.94 (3.47–9.20) 6.94 (3.47–6.94)
Indirect costs type 5 0.99 ± 0.50 0.91 ± 0.41 .11
0.91 (0.47–1.37) 0.91 (0.46–0.91)
Total cost, € 427.07 ± 639.20 226.55 ± 148.88 .03
∗
274.35 (149.25–484.22) 216.94 (58.49–330.36)
Data expressed as n (%) or mean ± standard deviation and median (interquartile range).
Indirect cost type 1 = activity-related outpatient unitary drug cost, indirect cost type 2 = remainder drug cost split across healthcare episodes, indirect cost type 3 = activity-adjusted unitary outpatients’ material
cost, indirect cost type 4 = activity-adjusted unitary material cost of other units supporting the quick diagnosis unit activity, indirect cost type 5 = remainder material costs split across healthcare episodes.
∗
Statistically significant differences.
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other medical consultations, endoscopy, anaesthetist consulta-
tion, structural cost, and all the indirect costs (Table 5).
3.3.2. Total cost greater vs smaller than the cohort median.
Cases with a highest total cost had a significantly longer time to
the diagnosis and a greater proportion of cases referred due to
cancer suggestive features, as well as more organic and cancer
final diagnoses. Almost all partial costs were greater in the former
than in the latter group, most remarkably for imaging costs, both
in absolute and relative terms (Table 6).
3.4. Cost correlation and regression analyses
Of all the demographic and clinical variables, only time-to-
diagnosis significantly but modestly showed a lineal correlation
with total costs (Fig. 1). In terms of partial costs correlations with
total costs, all correlations were significant, with the linear
correlation between imaging and total costs being the strongest
one (Table 7, Fig. 2).
In the binary logistic regression model with total cost
dichotomized according to the median as dependent variable,
and with sex, age, referral due to cancer suggestive features, time-
Table 4
Comparative statistics between final diagnosis of cancer vs noncancer.
Cancer final diagnose (n=58) Noncancer final diagnose (n=331) P value
Sex (women) 31 (53%) 184 (56%) .78
Age, yrs 68.28 ± 15.96 60.51 ± 20.22 .01
∗
71.5 (61.00–79.25) 64 (45–77)
Time-to-diagnosis, d 13.33 ± 14.81 24.86 ± 36.57 .15
8 (2–21) 12 (1–31)
Referral reason (cancer suggestive features) 37 (64%) 64 (19%) <.000001
∗
Final diagnosis (organic cause) 58 (100%) 258 (78%) .000004
∗
Physician costs 42.02 ± 15.10 37.11 ± 12.21 .02
∗
36.37 (36.37–48.50) 36.37 (24.25–48.50)
Laboratory costs 115.77 ± 134.92 105.73 ± 85.01 .93
146.92 (0.00–146.92) 146.92 (0.00–146.92)
Imaging costs 387.83 ± 584.62 78.65 ± 141.24 <.000001
∗
218.26 (0.00–593.05) 8.34 (0.00–113.02)
Cytology/biopsy costs 72.57 ± 125.77 5.62 ± 33.63 <.000001
∗
0.00 (0.00–86.53) 0.00 (0.00–0.00)
Pathology costs 6.79 ± 6.47 1.12 ± 3.25 <.000001
∗
7.83 (0.00–12.89) 0.00 (0.00–0.00)
Other medical consultation costs 11.29 ± 13.02 5.79 ± 10.35 .001
∗
0.00 (0.00–24.25) 0.00 (0.00–0.00)
Endoscopy costs 32.87 ± 72.71 19.18 ±56.79 .10
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Surgeon consultation costs 7.53 ± 11.32 2.05 ± 6.76 <.000001
∗
0.00 (0.00–24.25) 0.00 (0.00–0.00)
Anesthetist consultation costs 8.32 ± 14.88 3.96 ± 11.01 .009
∗
0.00 (0.00–8.62) 0.00 (0.00–0.00)
Operation room costs 9.44 ± 51.73 3.61 ± 51.09 .049
∗
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Admissions costs 105.88 ± 561.27 30.65 ± 371.14 .015
∗
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Costs of referral to tertiary hospital 0.00 ± 0.00 6.02 ± 39.13 .18
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Structural costs 5.79 ± 2.98 4.87 ± 2.38 .12
4.73 (4.73–7.10) 4.73 (2.37–7.10)
Indirect costs type 1 2.38 ± 1.26 1.95 ± 1.13 .015
∗
1.71 (1.71–2.57) 1.71 (0.86–2.57)
Indirect costs type 2 0.52 ± 0.32 0.42 ± 0.30 .005
∗
0.33 (0.33–0.65) 0.33 (0.16–0.49)
Indirect costs type 3 3.07 ± 1.56 2.54 ± 1.34 .004
∗
2.35 (2.35–3.52) 2.35 (1.17–3.52)
Indirect costs type 4 8.27 ± 4.23 6.95 ± 3.30 .040
∗
6.94 (6.13–10.40) 6.94 (3.47–9.29)
Indirect costs type 5 1.13 ± 0.57 0.95 ± 0.46 .014
∗
0.91 (0.91–1.37) 0.91 (0.46–1.37)
Total cost, € 821.48 ± 955.51 313.55 ± 457.80 <.000001
∗
529.07 (200.26–1048.33) 222.57 (117.90–400.74)
Data expressed as n (%) or mean ± standard deviation and median (interquartile range).
Indirect cost type 1 = activity-related outpatient unitary drug cost, indirect cost type 2 = remainder drug cost split across healthcare episodes, indirect cost type 3 = activity-adjusted unitary outpatients’ material
cost, indirect cost type 4 = activity-adjusted unitary material cost of other units supporting the quick diagnosis unit activity, indirect cost type 5 = remainder material costs split across healthcare episodes.
∗
Statistically significant differences.
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to-diagnosis and imaging cost as independent variables or
predictors, only time-to-diagnosis and imaging cost were
significantly associated with a greater cost (Table 8).
In the multiple linear regression model considering total cost as
a quantitative variable and the outcome, and the same variables
as above as the predictors, only the imaging costs were
independent predictors (beta=0.656, B=1.365, 95% CI=
1.198–1.531, P< .0001).
4. Discussion
In this single-center retrospective longitudinal study carried out at
a district hospital, we have observed that the cost of patients
referred due to cancer suggestive symptoms was greater than that
of those with other referral reasons. Likewise, a final cancer
diagnosis also implied a higher cost than other noncancer
diagnoses. Longer time-to-diagnosis was associated with greater
costs too. Of all subcosts relative to the different procedures,
ancillary tests and consultations, the one showing a stronger
correlation with total cost was the imaging cost. Both time-to-
diagnosis and imaging cost were significant predictors of total
costs in binary logistic regression, with imaging costs being a
significant predictor in multiple linear regression.
Despite the study limitations (retrospective analysis and single-
center setting), its design is distinct due to the use of the micro-
costing approach. Micro-costing consists in a comprehensive and
Table 5
Comparative statistics between cases with time-to-diagnosis over vs under the median time-to-diagnosis.
Time > 12 d (n=190) Time 12 d (n=198) P value
Sex (women) 99 (52%) 117 (59%) .18
Age, yrs 61.84 ± 19.27 61.77 ± 20.45 .95
66 (46–78) 64 (45–79)
Referral reason (cancer suggestive features) 48 (25%) 52 (26%) .91
Final diagnosis (organic cause) 155 (82%) 163 (82%) .89
Final diagnosis (cancer) 23 (12%) 34 (17%) .20
Physician costs 45.31 ± 13.17 30.99 ± 7.67 <.000001
∗
36.37 (36.37–48.50) 24.25 (24.25–36.37)
Laboratory costs 134.08 ± 79.62 79.96 ± 77.12 <.000001
∗
146.92 (118.60–146.92) 95.91 (0.00–146.92)
Imaging costs 177.94 ± 350.17 73.94 ± 181.46 <.000001
∗
87.93 (0.00–218.26) 0.00 (0.00–79.28)
Cytology/biopsy costs 16.61 ± 62.03 14.70 ± 62.45 .27
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Pathology costs 2.61 ± 4.99 1.32 ± 3.60 .002
∗
0.00 (0.00–7.83) 0.00 (0.00–0.00)
Other medical consultation costs 7.78 ± 11.62 5.39 ± 10.11 .036
∗
0.00 (0.00–24.25) 0.00 (0.00–0.00)
Endoscopy costs 29.68 ± 68.76 13.21 ± 48.03 .006
∗
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Surgeon consultation costs 3.06 ± 8.07 2.69 ± 7.64 .64
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Anesthetist consultation costs 6.53 ± 13.55 2.79 ± 9.42 .002
∗
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Operation room costs 7.41 ± 69.01 1.70 ± 23.87 .30
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Admissions costs 63.24 ± 541.83 21.58 ± 201.95 .95
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Costs of referral to tertiary hospital 7.53 ± 45.71 2.85 ± 23.65 .18
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Structural costs 6.47 ± 2.57 3.67 ± 1.50 <.000001
∗
4.73 (4.73–7.10) 2.37 (2.37–4.73)
Indirect costs type 1 2.62 ± 1.27 1.46 ± 0.66 <.000001
∗
2.48 (1.71–3.07) 1.24 (0.86–1.71)
Indirect costs type 2 0.57 ± 0.35 0.31 ± 0.18 <.000001
∗
0.49 (0.33–0.65) 0.33 (0.16–0.33)
Indirect costs type 3 3.39 ± 1.47 1.91 ± 0.81 <.000001
∗
2.85 (2.35–3.89) 1.42 (1.17–2.35)
Indirect costs type 4 9.20 ± 3.55 5.26 ± 2.14 <.000001
∗
6.94 (6.94–10.40) 3.47 (3.47–6.94)
Indirect costs type 5 1.26 ± 0.50 0.71 ± 0.29 <.000001
∗
0.94 (0.91–1.39) 0.47 (0.46–0.91)
Total cost, € 519.00 ± 728.30 264.43 ± 365.65 <.000001
∗
359.99 (220.87–532.64) 179.69 (53.34–323.61)
Data expressed as n (%) or mean ± standard deviation and median (interquartile range).
Indirect cost type 1 = activity-related outpatient unitary drug cost, indirect cost type 2 = remainder drug cost split across healthcare episodes, indirect cost type 3 = activity-adjusted unitary outpatients’ material
cost, indirect cost type 4 = activity-adjusted unitary material cost of other units supporting the quick diagnosis unit activity, indirect cost type 5 = remainder material costs split across healthcare episodes.
∗
Statistically significant differences.
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case-by-case real cost analysis, as opposed to the cost-minimiza-
tion analysis,[13] which assumes that average costs apply to all
cases. Hence, micro-costing is a more reliable and accurate
approach to assess the actual costs of a healthcare process.
Indeed, micro-costing has been applied in several fields of
medicine, such as thyroid surgery, liver transplantation, human
immunodeficiency virus, and intensive care units care in both
western and emerging countries.[14–19] In terms of QDUs, only 2
previous studies have been reported where this methodology was
applied,[20,21] with both focusing on comparing the QDU costs
with the costs of hospitalization for the same conditions. While
micro-costing theoretically also offers an avenue to identify
predictors of the total cost out of the different subcosts, to the best
of our knowledge this approach has not been previously applied
to identify predictors of QDU costs.
By using the micro-costing approach, both cancer suggestive
symptoms and a final cancer diagnosis were associated with
higher costs in our study. This observation agrees with the results
of a previous cost-minimization study conducted at a university
high-complexity hospital, where the estimated cost per patient for
nononcologic anemia was lower than that of both lymphoma and
lung cancer (anemia 652.46€; lymphoma 976.01€; lung cancer
1030.79€)[13]. Remarkably, though, under our micro-costing
assessment the median costs per patient according to cancer
Table 6
Comparative statistics between cases with total cost over vs under the median of the total cost.
Cost >259.97€ (n=203) Cost 259.97€ (n=203) P value
Sex (women) 116 (57%) 111 (55%) .69
Age, yrs 62.49 ± 18.26 61.19 ± 21.14 .79
66 (50–77) 64 (45–80)
Time-to-diagnosis, d 31.48 ± 32.78 15.31 ± 34.27 <.000001
∗
21.00 (8.00–42.50) 6.00 (0.00–14.75)
Referral reason (cancer suggestive features) 74 (36%) 32 (16%) .000003
∗
Final diagnosis (organic cause) 166 (82%) 153 (75%) .050
∗
Final diagnosis (cancer) 43 (21%) 15 (7%) .00005
∗
Physician costs 44.62 ± 14.83 31.78 ± 7.90 <.000001
∗
36.37 (36.37–48.50) 36.37 (24.25–36.37)
Laboratory costs 152.03 ± 93.80 64.14 ± 69.81 <.000001
∗
146–92 (146.92–146.92) 0.00 (0.00–146.92)
Imaging costs 247.24 ± 364.72 11.66 ± 31.91 <.000001
∗
150.83 (49.02–283.96) 0.00 (0.00–8.34)
Cytology/biopsy costs 29.85 ± 83.54 0.17 ± 0.77 <.000001
∗
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Pathology costs 3.74 ± 5.54 0.15 ± 1.09 <.000001
∗
0.00 (0.00–7.83) 0.00 (0.00–0.00)
Other medical consultation costs 10.03 ± 12.21 2.99 ± 7.99 <.000001
∗
0.00 (0.00–24.25) 0.00 (0.00–0.00)
Endoscopy costs 43.51 ± 79.52 0.00 ± 0.00 <.000001
∗
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Surgeon consultation costs 4.06 ± 9.08 1.67 ± 6.16 .002
∗
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Anesthetist consultation costs 9.34 ± 15.36 0.17 ± 2.42 <.000001
∗
0.00 (0.00–34.47) 0.00 (0.00–0.00)
Operation room costs 8.59 ± 70.66 0.00 ± 0.00 .045
∗
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Admissions costs 80.23 ± 558.76 0.00 ± 0.00 .014
∗
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Costs of referral to tertiary hospital 8.93 ± 48.67 0.89 ± 10.57 .053
0.00 (0.00–0.00) 0.00 (0.00–0.00)
Structural costs 6.33 ± 2.90 3.83 ± 1.54 <.000001
∗
4.73 (4.73–7.10) 4.73 (2.37–4.73)
Indirect costs type 1 2.61 ± 1.39 1.49 ± 0.65 <.000001
∗
2.47 (1.71–3.43) 1.71 (0.86–1.71)
Indirect costs type 2 0.57 ± 0.37 0.31 ± 0.17 <.000001
∗
0.49 (0.33–0.65) 0.33 (0.16–0.33)
Indirect costs type 3 3.35 ± 1.63 1.97 ± 0.81 <.000001
∗
2.85 (2.35–4.27) 2.34 (1.17–2.35)
Indirect costs type 4 8.96 ± 4.02 5.51 ± 2.23 <.000001
∗
6.94 (6.93–10.40) 6.13 (3.47–6.94)
Indirect costs type 5 1.23 ± 0.56 0.74 ± 0.30 <.000001
∗
0.94 (0.91–1.40) 0.91 (0.46–0.91)
Data expressed as n (%) or mean ± standard deviation and median (interquartile range).
Indirect cost type 1 = activity-related outpatient unitary drug cost, indirect cost type 2 = remainder drug cost split across healthcare episodes, indirect cost type 3 = activity-adjusted unitary outpatients’ material
cost, indirect cost type 4 = activity-adjusted unitary material cost of other units supporting the quick diagnosis unit activity, indirect cost type 5 = remainder material costs split across healthcare episodes.
∗
Statistically significant differences.
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suggestive features and a final diagnosis of cancer were 430.75€
and 529.07€, respectively. Hence, and albeit not directly
comparable due to different methodologies (cost-minimization
vs micro-costing) and study groups (noncancer anemia vs
lymphoma and lung cancer in one case, and cancer vs noncancer
in our case), this finding suggests that district hospital QDUmight
be more efficient than university hospital QDU.
While previous studies have shown that QDU is not inferior to
hospitalization in terms of time-to-diagnosis, the impact of time-
to-diagnosis on costs has not been properly evaluated. In our
study, the association of longer time-to-diagnosis with higher
costs could be a result of longer time-to-diagnosis being a proxy
ofmore complex cases requiringmore diagnostic tests. Therefore,
it is unlikely that merely reducing the time-to-diagnosis rather
than the number of diagnostic tests could result in cost saving,
due to the marginal contribution of personal and structural costs
to the total cost of the QDU process. Nevertheless, reducing the
time-to-diagnosis would still be valuable in terms of improved
patient-perceived quality.
In the assessment of linear correlations between partial and
total costs, all were significantly correlated, and imaging costs
displayed the strongest association. Accordingly, imaging costs
surfaced as a significant predictor of the total cost of the QDU
process both in the binary logistic regression model considering
the total costs dichotomized according to the median, and in the
multiple regression model with total costs as the quantitative
dependent variable. It could be argued that this association was
driven by the fact that imaging tests are costly and commonly
used in the QDU process. Should one conclusion of our results be
that cutting imaging costs would result in QDU costs saving, this
strategy would be jeopardized by the fact that most such patients
do need imaging for diagnosis and staging. Nevertheless, more
stringent protocols trying to avoid overuse of imaging in cases
with a very low likelihood of cancer, and to limit the number of
imaging tests in cases with high cancer suspicion to those strictly
necessary to identify the tumor, guide the biopsy and complete
the staging, might eventually overcome this challenge. There are
avenues for reducing imaging cost that do not rely on avoiding a
given imaging test but rather simplifying it by means of
abbreviated protocols. For example, there is one such experience
with abbreviated magnetic resonance imaging protocol for breast
Figure 1. Correlation between cost and time-to-diagnosis.
Table 7
Correlations between partial costs and total cost (n=406).
Rho P value
Physician cost 0.63 <.000001
∗
Laboratory cost 0.63 <.000001
∗
Imaging cost 0.77 <.000001
∗
Cytology/biopsy cost 0.40 <.000001
∗
Pathology cost 0.53 <.000001
∗
Other medical consultation cost 0.36 <.000001
∗
Endoscopy cost 0.37 <.000001
∗
Surgeon consultation cost 0.18 .0003
∗
Anesthetist cost 0.41 <.000001
∗
Operation room cost 0.14 .005
∗
Admissions cost 0.21 .00003
∗
Referral tertiary hospital cost 0.13 .009
∗
Structural cost 0.60 <.000001
∗
Indirect cost 1 0.62 <.000001
∗
Indirect cost 2 0.59 <.000001
∗
Indirect cost 3 0.62 <.000001
∗
Indirect cost 4 0.58 <.000001
∗
Indirect cost 5 0.62 <.000001
∗
Indirect cost type 1= activity-related outpatient unitary drug cost, indirect cost type 2 = remainder drug
cost split across healthcare episodes, indirect cost type 3= activity-adjusted unitary outpatients’material
cost, indirect cost type 4 = activity-adjusted unitary material cost of other units supporting the quick
diagnosis unit activity, indirect cost type 5 = remainder material costs split across healthcare episodes.
∗
statistically significant association.
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cancer that has proven to reduce the imaging costs for this
diagnosis.[22]
This study has both limitations and strengths. The main
limitations are the retrospective design along with the fact of
being a single-center study, as well as the lack of direct
comparison to hospitalization costs. However, these limitations
are, at least partly, compensated for by the strengths of the
reasonably large sample size and the detailed micro-costing
approach[23]. The latter has allowed for reliable identification of
cost-predictors. This along with the prior knowledge that QDUs
are cost-effective relative to conventional hospitalization[10,11]
supports the notion that further cost decrease in QDU might
represent an additional advantage compared to hospitalization-
based diagnosis. However, studies with direct comparison will be
needed to confirm or not this hypothesis. Another asset of our
study is the longitudinal design with a long study period.
5. Conclusion
In summary, our study has identified a number of predictors of
the total QDU costs. Some of these are only partly modifiable
such as the referral reason, because one of the goals of the QDU is
actually to speed up the diagnosis of cases with features
suspicious of an underlying neoplasm, which is one of the
contributors to the QDU cost. Nevertheless, improved protocols
and communication between the primary care centers and the
hospital-based QDU might lead to a reduction of noncancer
suspicious referrals, which albeit not being predictors of
increased costs, do also have an impact on the cost burden.
Some other predictors, mostly imaging costs, might be more
addressable, even if not easily. For instance, protocols promoting
lesser expensive screening tests with high negative predictive
value might result in less additional and costly imaging tests.
Another avenue is that of simplifying certain imaging protocols
reducing the time of acquisition or the number of sequences in
magnetic resonance imaging studies, for example. These actions
could add to the already demonstrated cost-effectiveness of
QDUs and potentially assist the sustainability of the national
health systems. This could be implemented and be beneficial not
only to QDUs in Spain but also in many developing nations,
where healthcare systems are severely constrained by financial
reasons.
Table 8
Binary logistic regressions with the total cost dichotomized according to its median value as outcome (dependent variable) and age, sex,
time-to-diagnosis, referral reason, and imaging costs as potential predictors (independent variables).
95% confidence interval
Total cost dichotomized according to median Odds ratio Lower margin Upper margin P value
Sex (women) 0.75 0.42 1.35 .34
Age, yrs 1.00 0.99 1.02 .77
Referral reason (suggestive of cancer) 1.01 0.46 2.24 .97
Time-to-diagnosis, d 1.01 1.002 1.02 .013
∗




Figure 2. Correlation between total cost and imaging cost.
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